Pricing

Biophytis (BPTS)

followers ·
Sector:
Industry:
CEO:
Stanislas Veillet
Employees:
30
SORBONNE UNIVERSITY, BC 9, BATIMENT A 4EME ETAGE, 4 PLACE JUSSIEU, PARIS, I0, 75001
33 1 44 37 23 00
Stock Split History
DateRatio
2023-03-30 1:10
Biophytis S.A. focuses on the development of therapeutics that slow degenerative processes and improve functional outcomes for patients suffering from age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available